Related Experiment Videos
Photodynamic therapy for corneal neovascularization.
R J Epstein1, R L Hendricks, D M Harris
1Department of Ophthalmology, Rush Medical College, University of Illinois, Chicago.
Cornea
|September 1, 1991
Summary
Photodynamic therapy (PDT) using a 514 nm argon laser effectively reduced corneal neovascularization (CNV) in mice. This method proved safer and more efficacious than previous approaches for treating IL-2-induced CNV.
Area of Science:
- Ophthalmology
- Laser Therapy
- Vascular Biology
Background:
- Corneal neovascularization (CNV) can impair vision.
- Previous photodynamic therapy (PDT) for CNV showed selectivity but caused collateral tissue damage.
- Interleukin-2 (IL-2) injection in mice reliably induces CNV.
Purpose of the Study:
- To evaluate the efficacy and safety of PDT using a 514 nm argon laser for treating IL-2-induced CNV.
- To determine if this modified PDT approach reduces toxicity compared to previous methods.
Main Methods:
- CNV was induced in mice via IL-2 injection.
- Mice received dihematoporphyrin ether (DHE) intravenously, followed by irradiation with a 514 nm argon laser.
- Treated eyes were compared to control groups (DHE only, laser only, untreated).
- Mean CNV areas were measured before and after treatment.
Main Results:
- PDT with the 514 nm laser significantly decreased CNV area in the treated group (Group I).
- Control groups showed no significant reduction in CNV.
- Complications included blepharitis (9%) and iris damage (18%) in the treated group.
- Histology confirmed no posterior segment damage.
Conclusions:
- PDT utilizing a 514 nm ophthalmic argon laser is a safe and effective treatment for IL-2-induced CNV in a mouse model.
- This approach offers a promising alternative for managing CNV with reduced toxicity.